Skip to main content
Indietro

Controlling Microbial Growth in the Body: Antimicrobial Drugs

Guida di studio - Note intelligenti

Appunti personalizzati basati sui tuoi materiali, ampliati con definizioni chiave, esempi e contesto.

Controlling Microbial Growth in the Body: Antimicrobial Drugs

Introduction to Antimicrobial Drugs

Antimicrobial drugs are essential tools in the treatment and prevention of infectious diseases. Their primary goal is to destroy or inhibit the growth of pathogenic microbes while minimizing harm to the host. The concept of selective toxicity is central to antimicrobial therapy, ensuring that drugs target microbial structures or functions not found in host cells.

  • Selective toxicity: The drug should harm the microbe without damaging host tissues.

  • Microbicidal vs. Microbistatic: Ideally, drugs should kill microbes (microbicidal) rather than merely inhibit their growth (microbistatic).

  • Prevention of resistance: Drugs should not easily lead to the development of microbial resistance.

Cartoon illustrating antibiotic resistance when antibiotics are not taken fully Table of definitions for chemotherapeutic drug, prophylaxis, antimicrobials, antibiotics, etc. Table: Characteristics of the Ideal Antimicrobial Drug

Pioneering Contributions in Antimicrobial Therapy

The development of antimicrobial drugs is rooted in the discoveries of several Nobel laureates:

  • Paul Ehrlich: Developed "magic bullets" like Salvarsan for syphilis.

  • Alexander Fleming: Discovered penicillin, the first true antibiotic.

  • Gerhard Domagk: Discovered sulfonamides, the first widely used antibiotics.

  • Selman Waksman: Discovered streptomycin and coined the term "antibiotic." Many antibiotics are natural metabolites of Streptomyces (bacteria) and molds such as Penicillium and Cephalosporium.

Portrait of Paul Ehrlich (blurred face) Portrait of Alexander Fleming (blurred face) Fleming's original plate showing mold and bacterial colonies

Mechanisms of Antimicrobial Action

Antimicrobial drugs target essential microbial structures and processes, exploiting differences between microbes and host cells. The main mechanisms include:

  • Inhibition of cell wall synthesis (e.g., beta-lactams, vancomycin, bacitracin)

  • Disruption of cell membrane integrity (e.g., polymyxins, polyenes)

  • Inhibition of protein synthesis (e.g., aminoglycosides, tetracyclines, macrolides)

  • Inhibition of nucleic acid synthesis (e.g., fluoroquinolones, rifamycins)

  • Inhibition of metabolic pathways (e.g., sulfonamides, trimethoprim)

Diagram showing targets of antimicrobial drugs in a bacterial cell

Inhibitors of Cell Wall Synthesis

Beta-Lactam Antibiotics

Beta-lactam antibiotics, including penicillins, cephalosporins, and carbapenems, inhibit bacterial cell wall synthesis by blocking the transpeptidase enzyme (also known as penicillin-binding proteins, PBPs). This prevents the formation of peptide cross-links in peptidoglycan, leading to cell lysis.

  • Penicillins: Penicillin G, methicillin

  • Cephalosporins, Carbapenems: Broader spectrum beta-lactams

  • Beta-lactamase inhibitors: Clavulanic acid protects beta-lactam drugs from enzymatic degradation (e.g., Augmentin = amoxicillin + clavulanic acid)

Diagram of peptidoglycan synthesis and beta-lactam action Diagram showing penicillin blocking transpeptidase enzyme Diagram showing beta-lactam antibiotics preventing peptide cross-links

Vancomycin and Bacitracin

  • Vancomycin: Binds to D-Ala-D-Ala termini of peptidoglycan precursors, blocking cross-linking. Effective against MRSA and Clostridium difficile infections.

  • Bacitracin: Inhibits the recycling of bactoprenol, a carrier molecule for peptidoglycan precursors. Used topically due to nephrotoxicity.

Diagram showing vancomycin blocking peptidoglycan elongation Diagram showing bacitracin blocking peptidoglycan synthesis

Isoniazid and Ethambutol

These drugs are used against Mycobacterium species (e.g., tuberculosis):

  • Isoniazid (INH): Inhibits mycolic acid synthesis.

  • Ethambutol: Inhibits synthesis of the mycobacterial cell wall outer membrane.

Diagram of mycobacterial cell wall structure Infographic of tuberculosis drugs and side effects

Inhibitors of Protein Synthesis

Ribosomal Targets

Prokaryotic ribosomes (70S) differ from eukaryotic ribosomes (80S), allowing selective targeting. However, mitochondrial ribosomes resemble prokaryotic ribosomes, which can lead to toxicity in host cells.

  • Aminoglycosides (e.g., streptomycin): Bind 16S rRNA of 30S subunit, causing misreading of mRNA.

  • Tetracyclines: Block tRNA binding to the 30S subunit, preventing protein elongation.

  • Macrolides (e.g., erythromycin): Bind 23S rRNA of 50S subunit, inhibiting peptide bond formation.

  • Chloramphenicol: Inhibits peptide bond formation; reserved for severe infections due to toxicity.

  • Oxazolidinones, Lincosamides: Inhibit initiation or elongation steps of translation.

Diagram comparing prokaryotic and eukaryotic ribosomes Diagram of antibiotics targeting translation steps Diagram of antibiotics binding to ribosomal subunits Diagram of antibiotics binding to 50S ribosomal subunit

Inhibitors of Cell Membrane Function

Few antibiotics target cell membranes due to similarities with host membranes. Notable examples include:

  • Polymyxins: Disrupt Gram-negative bacterial membranes; used topically due to toxicity.

  • Polyenes (e.g., amphotericin B, nystatin): Bind ergosterol in fungal membranes, forming pores.

  • Azoles: Inhibit ergosterol synthesis in fungi.

Inhibitors of Metabolic Pathways

Some antibiotics inhibit unique microbial metabolic pathways, such as folic acid synthesis:

  • Sulfonamides: Competitive inhibitors of PABA, blocking folic acid synthesis.

  • Trimethoprim: Inhibits a later step in folic acid synthesis.

Inhibitors of Nucleic Acid Synthesis

  • Fluoroquinolones (e.g., ciprofloxacin): Inhibit DNA gyrase and topoisomerase IV, blocking DNA replication.

  • Rifamycins (e.g., rifampin): Inhibit bacterial RNA polymerase, blocking transcription.

  • Metronidazole: Causes DNA strand breaks in anaerobic bacteria and protozoa.

Side Effects and Resistance

  • Common side effects: Allergic reactions (e.g., penicillin rash), toxicity (e.g., nephrotoxicity, ototoxicity), and disruption of normal flora.

  • Resistance mechanisms: Enzymatic degradation (e.g., beta-lactamases), target modification, efflux pumps, and reduced permeability.

Summary Table: Key Antimicrobial Drug Classes and Targets

Drug Class

Target

Example(s)

Notes

Beta-lactams

Cell wall synthesis

Penicillins, cephalosporins

Inhibit transpeptidase

Glycopeptides

Cell wall synthesis

Vancomycin

Binds D-Ala-D-Ala

Bacitracin

Cell wall synthesis

Bacitracin

Blocks bactoprenol recycling

Aminoglycosides

Protein synthesis (30S)

Streptomycin

Misreading of mRNA

Tetracyclines

Protein synthesis (30S)

Doxycycline

Blocks tRNA binding

Macrolides

Protein synthesis (50S)

Erythromycin

Blocks peptide bond formation

Polymyxins

Cell membrane

Polymyxin B

Disrupts membrane

Sulfonamides

Folic acid synthesis

Sulfamethoxazole

Blocks PABA utilization

Fluoroquinolones

DNA synthesis

Ciprofloxacin

Inhibits DNA gyrase

Rifamycins

RNA synthesis

Rifampin

Inhibits RNA polymerase

Pearson Logo

Study Prep